Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

USP Monographs Should Be Developed By Public/Private Partnership, Congress Says

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA is urged to seek adequate funding in the FY 2006 budget request to support the effort to increase the number of formal monographs for drug compounding, the report for the FY 2005 spending bill states. The bill provides FDA with $1.79 bil.

You may also be interested in...



USP Will Consider Setting Pharmacy Compounding Standards

The U.S. Pharmacopeia will consider a resolution on setting pharmacy compounding standards at its upcoming 2005 convention

USP Will Consider Setting Pharmacy Compounding Standards

The U.S. Pharmacopeia will consider a resolution on setting pharmacy compounding standards at its upcoming 2005 convention

FDA Drug Compounding Enforcement Continues With Teregen Labs Citation

The Gentere subsidiary distributes compounded drug products for those commercially available and without valid prescriptions, an FDA warning letter states. The agency also cites the firm for cGMP violations.

Topics

UsernamePublicRestriction

Register

OM004674

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel